# Treatment Duration Increment and Pharmacodynamic Study of CX-4945 in Patients With Basal Cell Carcinoma (BCC)

> **NCT03897036** · PHASE1 · COMPLETED · sponsor: **Senhwa Biosciences, Inc.** · enrollment: 25 (actual)

## Conditions studied

- Carcinoma, Basal Cell

## Interventions

- **DRUG:** CX-4945

## Key facts

- **NCT ID:** NCT03897036
- **Lead sponsor:** Senhwa Biosciences, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-04-16
- **Primary completion:** 2024-01-25
- **Final completion:** 2024-01-25
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2025-05-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03897036

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03897036, "Treatment Duration Increment and Pharmacodynamic Study of CX-4945 in Patients With Basal Cell Carcinoma (BCC)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03897036. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*